Carbidopa, Levodopa, And Entacapone Tablet, Film Coated
NDC Package 52483-5901-0

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is approaching its end of marketing date. An upcoming end of marketing date means the product has been delisted but will remain in the NDC database until the end of marketing date is reached. In most cases, the FDA advises firms to use the expiration date of the last lot produced as the end marketing date, reflecting the possibility that the product may still be available even after manufacturing has stopped.
This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Carbidopa, Levodopa, And Entacapone tablets is a drug for further processing. This formulation utilizes a tablet, film coated delivery system. Marketed by Orion Corporation, Orion Pharma, this product is identified by NDC 52483-5901.

Identification & Billing

NDC Package Code
52483-5901-0
Package Description
1 BAG in 1 DRUM / 51000 TABLET, FILM COATED in 1 BAG
Product Code
52483-5901
11-Digit Billing Format
52483590100

Clinical Specifications

Proprietary Name
Carbidopa, Levodopa, And Entacapone
Non-Proprietary Name
Carbidopa, Levodopa, And Entacapone
Substance Name
Carbidopa; Entacapone; Levodopa
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Active Ingredient(s)

Regulatory & Marketing

Labeler Name
Orion Corporation, Orion Pharma
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
03-24-2014
End Marketing Date
07-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 52483-5901-0 identifies a specific commercial package of 1 bag in 1 drum / 51000 tablet, film coated in 1 bag of Carbidopa, Levodopa, And Entacapone (UNFINISHED drug), drug for further processing labeled by Orion Corporation, Orion Pharma. This tablet, film coated is formulated for use and contains carbidopa; entacapone; levodopa as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Orion Corporation, Orion Pharma on March 24, 2014.

How is this Orion Corporation, Orion Pharma product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 52483590100. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
52483-5901-0
11-Digit CMS (5-4-2)
52483-5901-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.